Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA)

August 30, 2018 updated by: Rabin Medical Center

Analgesic Efficacy of Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Trial to Compare Postoperative Clinical Outcomes

Total knee arthroplasty (TKA) is associated with severe postoperative pain. Multimodal analgesia, including peripheral nerve block, is recommended for post-operative pain relief 1. Perineural analgesia offers the advantage of extended pain relief up to 24 hours after surgery2.

This is a prospective, randomized control trial designed to compare the analgesic efficacy of the adductor canal block (ACB) performed immediately before or immediately after primary total knee arthroplasty (TKA). The primary objective of this study is to measure pain score associated with knee motion following TKA among patients receiving ACB as part of their analgesic regimen for TKA. Secondary end points include assessment of postoperative ambulation, range of motion, pain at rest, opioid consumption, and patient satisfaction between the two analgesic approaches. The investigators hypothesize that ACB before the surgery will reduce a patient's postoperative pain and improve patient satisfaction.

All consecutive patients undergoing primary TKA will be recruited for enrollment in the study. Patients will be for randomized preoperatively to receive either preemptive ABC (PreACB) or postoperative ABC (PostACB). Patients randomized to the PreACB group will receive the block prior to incision. Patients randomized to the PostACB group will receive the block at the end of the surgery. Both techniques are in accordance to the standard of care at our institute. All patients will have the ACB done by a regional anesthesiologist in the regional anesthesia unit, or in the operating room. Patient medical history will be obtained and blocks will be placed per usual protocol. Operative and anesthetic details, including medications given, will be recorded.

Pain scores and pain medications given in the PACU will be recorded. Supplementary analgesics will be provided per institutional PACU protocol. Study data will be recorded for up to 72 hours or until patient discharge. A follow-up will occur in 4- 6 weeks at the orthopedic follow-up appointment to evaluate the patient's late pain scores and overall satisfaction. Data will be analyzed both at the conclusion of the study and at several intervals prior to completion of the study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

D. Research Design and Methods

Inclusion Criteria:

The study is a prospective, randomized controlled clinical trial comparing two methods of regional analgesia for primary TKA. All adult primary TKA patients are eligible for inclusion in the study.

Exclusion criteria:

  • Allergy to local anesthetics or to systemic opioids
  • Contraindication to regional anesthesia technique, such as local infection or coagulopathy
  • Sensory/motor disorder involving operative limb
  • Requirements of more than 30 mg morphine equivalent daily prior to surgery
  • ASA 4 or greater
  • Psychiatric or cognitive disorders
  • Incarceration
  • Renal insufficiency with Cr > 2.0
  • Hepatic failure
  • Pregnancy
  • Age under 18 years Potential risks for the procedure, which will be explained to the patient, include: bleeding, local infection, local anesthetic toxicity. All are commonly listed as rare complications of the procedures.

After consenting to participation and upon randomization, ACBs will be placed either in the regional anesthesia bay or the OR prior to anesthesia induction and surgery, or in the OR immediately upon completion of surgery.

For participating patients, the following data will be collected by the research staff: ASA physical status, age, height, weight, gender, intra- and post operative quantitative opiate use (expressed as morphine equivalent), numeric VAS scores, KSS score (form included) and QoR score (form included).

Those collecting data will be blinded from randomization of patients to either research group.

Intraoperative care:

Intraoperative anesthesia will be achieved using a general anesthetic technique. Intraoperative analgesia will be administered per anesthesiologists' discretion.

All patients will have cemented total knee utilizing a medial parapatellar approach, including patellar resurfacing. A tourniquet will be used in all cases. Posterior capsule infiltration will be done with 20cc of 0.25% bupivacaine, as the preferred method of providing sacral plexus analgesia 5-6, per current institutional protocol.

ACB Procedure Details Patients will lie in the supine position. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. The skin will be disinfected with 2% Chlorhexidine and the ultrasound probe placed in a sterile sleeve. The femoral artery is identified with a high frequency linear transducer (Philips 4-12L linear transducer with a frequency of 6-12 MHz, Milwaukee, WI or ) proximal to the operative knee. The appropriate location for injection will be determined by following the femoral artery cephalad until the artery is directly posterior to the Sartorius muscle. At this level, the saphenous nerve is located lateral to the femoral artery. An 18g insulated sonographic Tuohy needle (Pajunk GmbH, Geisingen, Germany) will be inserted in an in-plane approach, under constant ultrasound visualization, through the Sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 20 cc of 0.5% ropivacaine will be injected gradually through the needle under visualization, with recurrent aspirations to verify absence of intra-vascular injection signs.

Data Collection Patients will be enrolled for the study during the orthopedic surgical appointment upon the scheduling of the surgery. Upon enrollment, patients will complete a baseline KSS questionnaire (attached), have a VAS pain score recorded, and have their pre-operative analgesic medication documented.

To assess the effect of pain with movement and overall strength, on POD 1, the patient will indicate their level of pain using VAS numeric scale (1-10). QoR questionnaire (attached) will be assessed 24 hours from the placement of the ACB. Overall analgesic medication consumption, both opioid (expressed as morphine equivalent) and non-opioid will be recorded for PODs 1-3.

The patients will also complete the KSS and the QoR questionnaires at the 4-6 week orthopedic follow-up appointment, as VAS scores and total analgesic medication will be documented.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Petach Tikvah, Israel
        • Rabin Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

The study is a prospective, randomized controlled clinical trial comparing two methods of regional analgesia for primary TKA. All adult primary TKA patients are eligible for inclusion in the study.

Exclusion Criteria:

  • Allergy to local anesthetics or to systemic opioids
  • Contraindication to regional anesthesia technique, such as local infection or coagulopathy
  • Sensory/motor disorder involving operative limb
  • Requirements of more than 30 mg morphine equivalent daily prior to surgery
  • ASA 4 or greater
  • Psychiatric or cognitive disorders
  • Incarceration
  • Renal insufficiency with Cr > 2.0
  • Hepatic failure
  • Pregnancy
  • Age under 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Patients receiving ACB before primary TKA

Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).

Patients randomized to this group will receive the block prior to incision after induction of general anesthesia
Drug: 0.5% ropivacaine
Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
Active Comparator: Patients receiving ACB after primary TKA

Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).

Patients randomized to this group will receive the block at the end of the surgery.
Drug: 0.5% ropivacaine
Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score associated with knee motion following TKA
Time Frame: 4-6 Weeks postoperatively
This study's primary endpoint the change in the patient's reported pain score on the preoperative visit, on postoperative day (POD) 1, and the patient's pain score reported on the 4-6 week follow- up visit. Pain score will be measured using a numeric verbal analogue scale (1-10). Pain will be measured using this scale on the pre-operative visit, and on POD1 prior to manipulation, with active (patient driven) movement and with passive (physician elicited) movement.
4-6 Weeks postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid consumption
Time Frame: 4-6 weeks postoperatively
This study secondary endpoints is to evaluate changes in opioid consumption throughout 24-48 hours postoperatively to the 4-6 weeks postoperatively.Opioid consumption will be documented by a member of the research team at 24 hours postoperatively, 48 hours postoperatively , and on the follow-up visit (4-6 weeks postoperatively) in order to identify reduction / increases in patient's opioid consumption trends.
4-6 weeks postoperatively
Patient satisfaction between the two analgesic approaches.
Time Frame: 24 hours postoperatively
Additional secondary endpoint of this study is to evaluate whether patient's satisfaction scores differ amongst the two analgesic approaches on the POD 1. Patient's satisfaction score will be measured using the Quality of Recovery (QoR) score, documented on POD 1.
24 hours postoperatively
Assessment of postoperative ambulation.
Time Frame: 4-6 weeks postoperatively
Additional secondary endpoint of this study include assessment of changes in ambulation the range of motion throughout the study participation, from the preoperative visit to the follow-up visit (4-6 weeks following surgery). Knee Society Score (KSS) will be documented on preoperative visit, on POD 1 and at the follow-up visit ( 4-6 weeks after surgery), to examine changes in ambulation.
4-6 weeks postoperatively
Assessment of postoperative pain at rest
Time Frame: 4-6 weeks postoperatively
Additional secondary endpoint of this study include assessment of changes in pain at rest using the KSS score throughout the study participation, from the preoperative visit to the follow-up visit (4-6 weeks following surgery). Knee Society Score (KSS) will be documented on preoperative visit, on POD 1 and at the follow-up visit ( 4-6 weeks after surgery), to examine changes in patients reported pain at rest.
4-6 weeks postoperatively
Thrombo-embolic complications
Time Frame: Up to 24 weeks
Complications of deep venous thrombosis, pulmonary embolus will be documented
Up to 24 weeks
Blood transfusion
Time Frame: Up to 24 weeks
Additional secondary endpoint of this study is to assess whether the different analgesic approaches effect bleeding complications, measured by the number of patients who receive transfusion of concentrated blood cells units throughout their hospital admission.
Up to 24 weeks
Non opioid analgesia consumption
Time Frame: 4-6 weeks postoperatively
This study secondary endpoints is to evaluate changes in non-opioid analgesia -non opioid medication consumption throughout 24-48 hours postoperatively to the 4-6 weeks after surgery. Non-opioid analgesia - non-opioid medication consumption will be recorded on pre-operative visit, on POD 1, and on the follow-up visit (4-6 weeks postoperatively) in order to identify reduction / increases in patient's non-opioid analgesia -non opioid medication consumption trends.
4-6 weeks postoperatively
Patient satisfaction with the two analgesic approaches 4-6 weeks postopertively
Time Frame: 4-6 weeks postoperatively
Additional secondary endpoint of this study is to evaluate whether patient's satisfaction scores differ among the two analgesic approaches at the follow-up visit (4-6 weeks postoperatively). Patient's satisfaction score will be measured using the Quality of Recovery (QoR) score, documented on follow-up visit.
4-6 weeks postoperatively
Abnormal hemoglobin concentration values
Time Frame: Up to 24 weeks
Additional secondary endpoint of this study is to assess whether the different analgesic approaches effect bleeding complications, measured by the percent of decline in patients' hemoglobin concentration throughout their hospital admission.
Up to 24 weeks
Duration of hospital stay
Time Frame: Up to 24 weeks
Additional secondary endpoint of this study is to assess whether the different analgesic approaches effect duration of hospital admission, measured by the length of stay in the hospital.
Up to 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rabin Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

August 21, 2016

First Submitted That Met QC Criteria

September 18, 2016

First Posted (Estimate)

September 21, 2016

Study Record Updates

Last Update Posted (Actual)

September 4, 2018

Last Update Submitted That Met QC Criteria

August 30, 2018

Last Verified

August 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0524-16-RMC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anesthesia, Regional

Clinical Trials on 0.5% ropivacaine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe